Roberto Martín-Asenjo

Roberto Martín-Asenjo

Auto-generated profile, based on publicly available information

Roberto Martín-Asenjo

Servicio de Cardiología, Hospital 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital, 12 de Octubre (imas12), Madrid, Spain

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Closed access
Gonzalo Luis Alonso SalinasGonzalo Luis Alonso Salinas
Gonzalo Luis Alonso Salinas
MSMarcelo Sanmartín
Marcelo Sanmartín
MIMarina Pascual Izco
Marina Pascual Izco
RARoberto Martín Asenjo
Roberto Martín Asenjo
ARAlejandro Recio-Mayoral
Alejandro Recio-Mayoral
JGJosé Luis Zamorano Gómez
José Luis Zamorano Gómez
Frailty is a biological condition that reflects a state of decreased physiological reserve and vulnerability to stressors. The role of frailty in acute coronary syndrome patients has not been fully explored. Our study aims to assess the prevalence of frailty and its impact on in-hospital adverse outcomes of patients aged ⩾75 years admitted for acute coronary syndrome. This prospective, observational study included patients aged ⩾75 years admitted due to type 1 myocardial infarction in four tertiary hospitals. Frailty was assessed by the SHARE-FI index. The primary endpoint was the combination of in-hospital death or non-fatal myocardial (re)infarction. Secondary endpoints included the assessment of individual rates of (re)infarction, mortality, stroke, major bleeding and the combination of in-hospital death, (re)infarction and mortality. A total of 202 patients were analysed. Frail patients (n=71, 35.1%) were older, more often women, had higher rates of comorbidities, and a higher risk profile according to GRACE, TIMI and CRUSADE scores at admission. The primary endpoint was significantly more frequent among frail patients (9.9% vs. 1.5%; P=0.006), as well as the combination of death, myocardial infarction and stroke (11.3% vs. 1.5%; P=0.002), driven mainly by a higher mortality rate (8.5% vs 0.8%; P=0.004). On multivariate analysis, frailty phenotype was an independent predictor of major adverse cardiac events (odds ratio 7.13; 95% confidence interval 1.43–35.42). Over one third of elderly patients with high-risk acute coronary syndrome are frail. Frailty phenotype is an important and independent prognostic marker in these patients.

1 February 2021 in American Heart Journal
Verified
Journal Article
Closed access
ACAlejandro Cortés-Beringola
Alejandro Cortés-Beringola
LVLourdes Vicent
Lourdes Vicent
RMRoberto Martín-Asenjo
Roberto Martín-Asenjo
EPElena Puerto
Elena Puerto
LDLaura Domínguez-Pérez
Laura Domínguez-Pérez
HBHéctor Bueno
Héctor Bueno

1 September 2014 in Resuscitation
Verified
Journal Article
Closed access
JGJulio Garcia-Tejada
Julio Garcia-Tejada
AJAlfonso Jurado-Román
Alfonso Jurado-Román
JRJesús Rodríguez
Jesús Rodríguez
MVMaite Velázquez
Maite Velázquez
FHFelipe Hernández
Felipe Hernández
JTJuan Tascón
Juan Tascón

1 February 2017 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
IPIsabel Montilla Padilla
Isabel Montilla Padilla
RMRoberto Martín-Asenjo
Roberto Martín-Asenjo
HBHéctor Bueno
Héctor Bueno

1 June 2018 in Gerontology
Verified
Journal Article
Closed access
PDF file
Gonzalo Luis Alonso SalinasGonzalo Luis Alonso Salinas
Gonzalo Luis Alonso Salinas
MSMarcelo Sanmartín
Marcelo Sanmartín
MIMarina Pascual Izco
Marina Pascual Izco
LRLuis Miguel Rincón
Luis Miguel Rincón
AMAlba Martin-Acuna
Alba Martin-Acuna
JZJosé Luis Zamorano
José Luis Zamorano
Background: Myocardial infarction (MI) patients are increasingly older, and common risk scores include chronological age, but do not consider chronic comorbidity or biological age. Frailty status reflects these variables and may be independently correlated with prognosis in this setting. Objective: This study investigated the impact of frailty on the prognosis of elderly patients admitted due to MI. Methods: This prospective and observational study included patients ≥75 years admitted to three tertiary hospitals in Spain due to MI. Frailty assessment was performed at admission using the Survey of Health, Ageing and Retirement in Europe Frailty Index (SHARE-FI) tool. The primary endpoint was the composite of death or non-fatal reinfarction during a follow-up of 1 year. Overall mortality, reinfarction, the composite of death, reinfarction and stroke, major bleeding, and readmission rates were also explored. Results: A total of 285 patients were enrolled. Frail patients (109, 38.2%) were older, with a higher score in the Charlson Comorbidity Index and with a higher risk score addressed in the GRACE and CRUSADE indexes. On multivariate analysis including GRACE, CRUSADE, maximum creatinine level, culprit lesion revascularization, complete revascularization, and dual antiplatelet therapy at discharge, frailty was an independent predictor of the composite of death and reinfarction (2.81, 95% CI 1.16–6.78) and overall mortality (3.07, 95% CI 1.35–6.98). Conclusion: Frailty is an independent prognostic marker of the composite of mortality and reinfarction and of overall mortality in patients aged ≥75 years admitted due to MI.

16 June 2017 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
ACAlejandro Cortés-Beringola
Alejandro Cortés-Beringola
DFDonna Fitzsimons
Donna Fitzsimons
APAntonio Pelliccia
Antonio Pelliccia
GMGuillermo Moreno
Guillermo Moreno
RMRoberto Martín-Asenjo
Roberto Martín-Asenjo
HBHéctor Bueno
Héctor Bueno
The prognosis of patients after acute coronary syndromes is still suboptimal, mainly due to the risk of recurrent adverse coronary events, which is greatest during the first year, but persists over one’s lifetime. Meaningful progress in preventing cardiovascular events has been achieved. However, there remains much room for improvement by embracing innovative therapies and investing in multidisciplinary approaches. Pharmacological interventions focused on optimising antithrombotic and lipid-lowering therapies are both pillars of secondary prevention that have seen recent ground-breaking advances. Moreover, new approaches in diabetic patients with cardiovascular disease and new targets for anti-inflammatory treatment may significantly improve prevention strategies in the future. However, pharmacological treatments are expensive and can have significant side effects. Developing better tools in order to identify high-risk patients and promote more personalised strategies for each patient should be an absolute priority. Furthermore, adherence to medication is still low and represents a real challenge; several strategies to improve low adherence to treatment are currently under discussion. Non-pharmacological interventions are also essential. Improving communication with patients and advanced surveillance for those secondary risk factors that may negatively impact prognosis are crucial. Encouraging multidisciplinary teams that work effectively to optimise all aspects of secondary prevention, including a cardiac rehabilitation programme, is the optimal approach. Current secondary prevention strategies and suggestions for areas of improvement are discussed in this manuscript. However, the question remains: will research in secondary prevention continue to focus on stronger and more expensive drugs, or is it time for us to embrace a more patient-centred clinical and research model?